| Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis. | |
| | |
MedLine Citation:
|
PMID: 19652526 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: Bone metastasis affects the majority of patients with advanced breast cancer and no adequate therapy exists. Bisphosphonates, like zoledronic acid, inhibit the osteolytic component of tumor growth in osseous tissues, but these drugs are not curative. The current study evaluated the combination of zoledronic acid with death receptor 5 agonists in an animal model of breast cancer bone metastasis. MATERIALS AND METHODS: Female athymic nude mice (age 4-6 weeks, n=35) were inoculated with 200,000 luciferase-positive MDA- MB-435 cells by injection into the left ventricle. Animals were immediately imaged by bioluminescence technique and placed into one of the following therapy groups: Saline, hTRA8, hTRA8 + zoledronic acid, mTRA8, mTRA8 + zoledronic acid, or zoledronic acid monotherapy. DR5 agonists were given at 200 microg/dose and zoledronic acid 5 microg/dose, with mice treated biweekly for 4.5 weeks and imaged weekly. RESULTS: Combination therapy containing either hTRA8 or mTRA8 with zoledronic acid significantly reduced the number of secondary lesions (7.67+2.2 and 7.5+1.7 lesions/mouse, respectively) compared to saline treated controls (12.1+/-1.56 lesions/mouse) as assessed by bioluminescence imaging (p<0.05). Additionally, monotherapy with hTRA8 resulted in a significant reduction in tumor number (8.3 +/- 2.9) compared to control animals. Total body tumor burden over time were significantly less in groups treated with hTRA8+zoledronic and mTRA8 + Zoledronic acid combination as compared with the saline control group. At day 33, both combination therapies and zoledronic acid monotherapy provided significant reduction in total tumor burden and tumor infiltration of hindlimbs by histomorphometry (p<0.05). CONCLUSION: DR5 agonists in combination with bisphosphonates may be an acceptable combination therapy to reduce breast cancer growth in bone. |
| | |
Authors:
|
April Adams Szafran; Karri Folks; Jason Warram; Diptiman Chanda; Deli Wang; Kurt R Zinn |
Related Documents
:
|
785936 - Tranexamic acid (amca) and late hyphaema. a double blind study in cataract surgery. 21875796 - 2,5-disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design a... 21894886 - Efficient and scalable one-pot synthesis of 2,4-dienols from cycloalkenones: optimized ... 3917666 - Oxidation and glucuronidation of valproic acid in male rats--influence of phenobarbital... 11354146 - Triterpenoid saponins from the leaves of ilex kudincha. 17136306 - Fatty acids reduce the tensile strength of fungal hyphae during cephalosporin c product... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cancer biology & therapy Volume: 8 ISSN: 1555-8576 ISO Abbreviation: Cancer Biol. Ther. Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-08-06 Completed Date: 2009-12-11 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101137842 Medline TA: Cancer Biol Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 1109-16 Citation Subset: IM |
Affiliation:
|
Department of Pathology, University of Alabama at Birmingham, 1670 University Boulevard, Birmingham, AL 35294-0019, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibodies, Monoclonal / administration & dosage, pharmacology* Antineoplastic Combined Chemotherapy Protocols / pharmacology* Apoptosis / drug effects Bone Density / drug effects Bone Density Conservation Agents / administration & dosage, pharmacology Bone Neoplasms / drug therapy, prevention & control*, secondary* Breast Neoplasms / drug therapy*, pathology Cell Line, Tumor Diphosphonates / administration & dosage, pharmacology* Female Humans Imidazoles / administration & dosage, pharmacology* Mice Mice, Nude Osteoclasts / drug effects, pathology Receptors, TNF-Related Apoptosis-Inducing Ligand / agonists*, immunology Xenograft Model Antitumor Assays |
| Grant Support | |
ID/Acronym/Agency:
|
5P30 CA 013148-36/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 0/Receptors, TNF-Related Apoptosis-Inducing Ligand; 118072-93-8/zoledronic acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Utility of the systemic inflammatory response syndrome (SIRS) criteria in predicting the onset of se...
Next Document: Spermidinyl-CoA-based HAT inhibitors block DNA repair and provide cancer-specific chemo- and radiose...